natriuretic-peptide--brain and Testicular-Neoplasms

natriuretic-peptide--brain has been researched along with Testicular-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for natriuretic-peptide--brain and Testicular-Neoplasms

ArticleYear
Longitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:10

    Cross-sectional studies showed that treatment with cisplatin chemotherapy for testicular cancer is associated with an increased incidence of cardiac dysfunction. We investigated longitudinal progression of and contributing factors to cardiac dysfunction in testicular cancer survivors.. Cardiac assessments were carried out before 10 months (range 7-15 months) and 6.9 years (range 4.9-9.7 years) after start of cisplatin-based chemotherapy, consisting of echocardiography [systolic function (left ventricular ejection fraction, LVEF), diastolic function (myocardial tissue velocities; tissue velocity imaging of early diastole, TVI Et)] and plasma biomarkers (N-Terminal pro brain natriuretic peptide, NT-proBNP; galectin-3).. In 37 patients [median age 34 years (range 24-51 years)], the incidence of abnormal TVI Et increased from 0% at baseline and 4.5% at 10 months (in 27 patients) to 16.7% at 6.9 years post-chemotherapy (P = 0.03). One patient developed LVEF <50%; no other systolic abnormalities occurred. Hypertension, obesity and age were associated with larger decreases in TVI Et. Changes in NT-proBNP and galectin-3 were not related to echocardiographic abnormalities.. In this longitudinal cohort study, we observed a gradual decline in diastolic parameters after cisplatin-based chemotherapy for testicular cancer, whereas the rate of systolic dysfunction remains low. The association of larger declines in diastolic parameters with hypertension and obesity stresses the need to monitor and treat cardiovascular risk factors.

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Disease Progression; Echocardiography; Etoposide; Galectin 3; Heart Diseases; Humans; Longitudinal Studies; Male; Middle Aged; Natriuretic Peptide, Brain; Testicular Neoplasms; Ventricular Dysfunction, Left; Young Adult

2011
Evaluation of sub-acute changes in cardiac function after cisplatin-based combination chemotherapy for testicular cancer.
    British journal of cancer, 2009, Jun-16, Volume: 100, Issue:12

    Long-term cardiovascular morbidity is increasingly observed in chemotherapy-treated testicular cancer survivors, but little is known of early sub-clinical changes in cardiac function. We prospectively evaluated cardiac function in testicular cancer patients by echocardiography. Systolic (Wall Motion Score Index) and diastolic (E/A-ratio and Tissue Velocity Imaging (TVI)) parameters, and serum levels of N-Terminal pro-Brain Natriuretic Peptide (NT-proBNP) were assessed before the start of chemotherapy and 1 year later. Echocardiography data were compared with an age-matched group of healthy controls. Forty-two patients treated with bleomycin, etoposide and cisplatin were evaluated (median age 27 years, range 18-50). Systolic function and E/A-ratio did not change, whereas the median TVI decreased (12.0 vs 10.0 cms(-1); P=0.002). Median levels of NT-proBNP increased (5 vs 18 pmoll(-1), P=0.034). Compared with controls, TVI before the start of chemotherapy was not significantly different. In conclusion, we found that at a median of 10 months after cisplatin-based treatment for testicular cancer, TVI decreased significantly, indicating a deterioration of diastolic cardiac function. Serum levels of NT-proBNP increased. The prognostic significance of these changes for future cardiovascular morbidity is not clear.

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cohort Studies; Echocardiography; Etoposide; Heart; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Orchiectomy; Peptide Fragments; Prognosis; Prospective Studies; Risk Factors; Testicular Neoplasms; Ventricular Dysfunction, Left; Young Adult

2009